UroCCR Database: French Research Network for Kidney Cancer (National Multidisciplinary Clinical and Biological Database on Kidney Cancer)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 30,000
- 试验地点
- 121
- 主要终点
- Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
研究概览
简要总结
Kidney cancer management has become increasingly complex with the diversification of treatment options and the integration of multidisciplinary care. To meet these challenges, the UroCCR network was established in France as a national registry and research platform dedicated to renal cancer. Funded by the French National Cancer Institute (INCa), UroCCR prospectively collects comprehensive real-world data on patient care and disease evolution, while systematically linking these records with annotated biological samples (plasma, urine, and both healthy and tumour tissues). For each case, more than one thousand variables may be recorded, covering clinical, imaging, and patient-reported information.
More than a registry, UroCCR is a collaborative network of clinical and research professionals using a shared, evolving tool that supports rapid implementation of studies and fosters active knowledge generation. Unlike retrospective registries or sample-centred biobanks, UroCCR offers prospective, patient-focused inclusion and a wide scope of investigation-from translational and technological research to clinical evaluation and social sciences. It also supports multiple ancillary studies, including retrospective analyses and prospective clinical or observational trials, and operates under a structured governance system with recognised national and international labels.
By combining a rigorously structured, multicentre dataset with linkage to the French national health data system (SNDS), the platform uniquely unites detailed clinical annotation with population-wide coverage, creating a high-value environment for advancing kidney cancer research and care.
详细描述
The UroCCR project is a national kidney cancer registry and research network designed to address the specific challenges of renal cell carcinoma (RCC) management. While general cancer registries such as FRANCIM provide valuable surveillance data, most large-scale registries lack the depth of clinical, biological, and longitudinal follow-up information necessary to advance research and enable comprehensive analyses of kidney cancer outcomes. UroCCR was created in 2011 to meet this need.
With over 21,000 cases collected from 58 centres across France, UroCCR is now one of the largest national databases dedicated to kidney cancer worldwide. The registry captures detailed clinical parameters, treatments and outcomes, complemented by patient-reported measures and socioeconomic data. Because management practices within UroCCR follow the recommendations of the French Association of Urology (AFU), the dataset closely reflects real-world practice and provides a reliable basis for comparison with national and European guidelines. Moreover, patient data can be reused across numerous studies, allowing researchers to explore multiple scientific questions without requiring new enrolments for each project.
A distinctive strength of UroCCR is its integration of multiple research dimensions. Beyond clinical outcomes, it evaluates quality of life and the social and economic impact of kidney cancer. The registry is linked to annotated biobanking and national medico-administrative datasets, enabling translational studies and health services research. Additionally, UroCCR supports multiple ancillary studies, both retrospective analyses based on real-world data and prospective studies including randomised clinical trials or observational cohorts.
The project benefits from robust governance structures, ensuring standardised procedures, data quality, and ethical oversight. It has also received various national and international labels, recognising its methodological rigour and excellence in research infrastructure.
Digital innovations developed within the network, such as UroConnect® for perioperative monitoring and UroPredict machine learning models for recurrence and survival prediction, highlight its commitment to advancing care through new technologies.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient with kidney cancer
- •Patient with no opposition to collection of its data for the study
排除标准
- 未提供
研究组 & 干预措施
Patients
Adult patients with kidney cancer
干预措施: Radical nephrectomy versus partial nephrectomy (according surgeon judgement) (Procedure)
结局指标
主要结局
Comparison of the rates of complications between radical nephrectomy and partial nephrectomy
时间窗: At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years
Operative time, ,
次要结局
- Safety and efficacy of medical treatment on kidney tumor size evolution(At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years)
- Dosage of creatininemia to assess the renal function after surgery(At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years)
- Progression of the tumor(At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years)
- Safety and efficacy of medical treatment on biological parameters(At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years)
- Dosage of MDRD GFR to assess the renal function after surgery(At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years)
- Comparison of the rates of mortality between radical nephrectomy and partial nephrectomy(At Month 3, Month 6, Month12, and then every year for 5 years and every 2 years for 10 years)